↓ Skip to main content

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Overview of attention for article published in Arthritis Research & Therapy, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity
Published in
Arthritis Research & Therapy, November 2015
DOI 10.1186/s13075-015-0849-1
Pubmed ID
Authors

Janet Pope, Clifton O. Bingham, Roy M. Fleischmann, Maxime Dougados, Elena M. Massarotti, Jürgen Wollenhaupt, Benjamin Duncan, Geoffroy Coteur, Michael E. Weinblatt

Abstract

The effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) was investigated in 1063 patients with rheumatoid arthritis (RA) from the REALISTIC trial (double-blind, placebo-controlled to week 12, open-label to week 28; randomized 4:1 [CZP:placebo]). Correlations between PROs and RA signs and symptoms, and the relative efficacy of these measures, were examined. Adults with RA and an inadequate response to at least one disease-modifying antirheumatic drug were enrolled. PROs assessed included physical function (using the Health Assessment Questionnaire-Disability Index), pain, fatigue, sleep disturbance, Patient Global Assessment of Disease Activity (PtGA), Routine Assessment of Patient Index Data 3 (RAPID3), and Rheumatoid Arthritis Disease Activity Index (RADAI). Early significant and clinically meaningful improvements in all PROs were observed to week 12 with CZP vs. placebo and were maintained to the end of the trial (week 28). At week 12, up to one-third more CZP patients showed improvements compared with placebo that were greater than or equal to the minimal clinically important difference (MCID) in fatigue, sleep problems, pain, PtGA, RADAI, and RAPID3. The changes in PROs were correlated with clinical measures of disease activity, including the Disease Activity Score in 28 joints using C-reactive protein as well as tender and swollen joint counts. Rapid improvements in PROs were seen in patients with RA treated with CZP. The magnitude of improvement exceeded the MCID in multiple domains and demonstrated that CZP improves aspects of health-related quality of life that are meaningful to patients and superior to placebo. PROs provide information complementary to clinical outcomes in assessment of treatment benefits. ClinicalTrials.gov identifier: NCT00717236 . Registered on 15 July 2008.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 49 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 16%
Student > Ph. D. Student 7 14%
Researcher 7 14%
Other 6 12%
Student > Doctoral Student 4 8%
Other 10 20%
Unknown 8 16%
Readers by discipline Count As %
Medicine and Dentistry 23 46%
Psychology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Biochemistry, Genetics and Molecular Biology 2 4%
Nursing and Health Professions 2 4%
Other 6 12%
Unknown 9 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2015.
All research outputs
#1,928,177
of 12,451,992 outputs
Outputs from Arthritis Research & Therapy
#485
of 1,983 outputs
Outputs of similar age
#59,493
of 337,850 outputs
Outputs of similar age from Arthritis Research & Therapy
#113
of 294 outputs
Altmetric has tracked 12,451,992 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,983 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,850 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 294 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.